

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF  
SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden	
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>McNulty Christopher</u>  (Last) (First) (Middle) <u>C/O INVIVO THERAPEUTICS</u> <u>HOLDINGS CORP.</u> <u>ONE KENDALL SQUARE, SUITE B14402</u>  (Street) <u>CAMBRIDGE MA</u> <u>02139</u>  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>03/29/2017</u>	3. Issuer Name <b>and</b> Ticker or Trading Symbol <u>INVIVO THERAPEUTICS HOLDINGS CORP. [ NVIV ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below)  <u>Chief Financial Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line)  <input checked="" type="checkbox"/> Form filed by One Reporting Person  Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	922	D	

Table II - Derivative Securities Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock option (right to buy)	(1)	11/18/2023	Common Stock	37,500	8.2	D	
Stock option (right to buy)	(2)	12/10/2024	Common Stock	9,375	4.2	D	
Stock option (right to buy)	(3)	07/31/2025	Common Stock	35,000	14.55	D	
Stock option (right to buy)	(4)	12/10/2025	Common Stock	18,800	7.37	D	
Stock option (right to buy)	(5)	06/13/2026	Common Stock	40,000	6.19	D	
Stock option (right to buy)	(6)	01/18/2027	Common Stock	75,000	4.35	D	

Explanation of Responses:

- 1. This option became exercisable as to 25% of the shares on November 18, 2014, and the remaining shares began to vest thereafter on a monthly basis in 36 equal monthly installments.
- 2. This option became exercisable as to 25% of the shares on December 10, 2015, and the remaining shares began to vest thereafter on a monthly basis in 36 equal monthly installments.
- 3. This option became exercisable as to 25% of the shares on July 31, 2016, and the remaining shares began to vest thereafter on a monthly basis in 36 equal monthly installments.
- 4. This option became exercisable as to 25% of the shares on December 10, 2016, and the remaining shares began to vest thereafter on a monthly basis in 36 equal monthly installments.
- 5. This option becomes exercisable as to 25% of the shares on June 13, 2017, and the remaining shares vest thereafter on a monthly basis in 36 equal monthly installments.
- 6. This option becomes exercisable as to 25% of the shares on January 18, 2018, and the remaining shares vest thereafter on a monthly basis in 36 equal monthly installments.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

/s/ Tamara L. Joseph, Attorney-in-Fact 03/31/2017

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## Power of Attorney

I, Christopher McNulty, the undersigned, hereby constitute and appoint Mark D. Perrin, Tamara Joseph, Molly Fox, Byron Crowe, Rosemary Reilly, and each of them individually, as my true and lawful attorney-in-fact to:

1.Complete and execute on my behalf, as a director of InVivo Therapeutics Holdings Corp., a Nevada corporation (the "Company"), Forms 3, 4, and 5 required to be filed by me under Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules and regulations thereunder;

2.Do and perform any and all acts for and on my behalf which may be necessary or desirable to complete and execute any such Forms 3, 4 and 5 and any amendment or amendments thereto, and timely file such forms with the U.S. Securities and Exchange Commission (the "SEC") and any stock exchange or similar authority, including without limitation the filing of a Form ID or any other application materials to enable me to gain or maintain access to the Electronic Data Gathering, Analysis and Retrieval system of the SEC; and

3.Seek or obtain, as my representative and on my behalf, information regarding transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and I hereby authorize any such person to release any such information to such attorney-in-fact and approve and ratify any such release of information; and

4.Take any other action of any type whatsoever in connection with the foregoing, which in the opinion of such attorney-in-fact may be of benefit to, in the best interest of, or legally required of me, it being understood that the documents executed by such attorney-in-fact on my behalf pursuant to this Power of Attorney shall be in such form and shall contain such information as such attorney-in-fact may approve in such attorney-in-fact's discretion.

I hereby grant to each of such attorneys-in-fact full power and authority to do and perform all and every act which is necessary, proper or desirable to be done in the exercise of any of the rights, powers and authority granted in this Power of Attorney, with full power of substitution and revocation, and I ratify and confirm every act that such attorney-in-fact lawfully performs or causes to be done by virtue of this Power of Attorney and the powers and authority granted herein.

I acknowledge that the attorneys-in-fact appointed in this Power of Attorney, in serving in such capacity at my request, are not assuming or relieving, and the Company is not assuming or relieving, any of my responsibilities to comply with Section 16 of the Exchange Act or the rules or regulations thereunder. I acknowledge that neither the Company nor the foregoing attorneys-in-fact assume (i) any liability for my responsibility to comply with the requirements of the Exchange Act, (ii) any liability of mine for any failure to comply with such requirements, or (iii) any obligation or liability of mine for profit disgorgement under Section 16(b) of the Exchange Act.

This Power of Attorney shall remain in full force and effect until I am no longer required to file Forms 3, 4 and 5 with respect to my holdings or transactions in securities issued by the Company, unless I earlier revoke this Power of Attorney in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of March 29, 2017.

/s/ Christopher McNulty  
Signature  
Print Name: Christopher McNulty